Is type A blood associated with an increased risk of gastric cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Blood Type A is Associated with Increased Gastric Cancer Risk

Yes, blood type A is associated with an approximately 20% increased risk of gastric cancer compared to other blood types, while blood type O appears protective. This association has been consistently demonstrated across multiple large-scale studies and represents a non-modifiable genetic risk factor that should be considered alongside other established risk factors when assessing gastric cancer risk 1, 2, 3.

Magnitude of Risk

The increased risk associated with blood type A is modest but clinically meaningful:

  • Blood type A individuals have a 1.20-fold increased risk (95% CI: 1.02-1.42) of gastric cancer compared to other blood types 1
  • Blood type AB also shows elevated risk with an odds ratio of 1.18 (95% CI: 1.02-1.36) in Chinese populations and 1.09 (95% CI: 1.03-1.16) in meta-analysis 2
  • Blood type O appears protective with a reduced risk (OR = 0.80; 95% CI: 0.72-0.88) compared to non-O blood groups 3

These findings have been validated in a large meta-analysis of 40 studies including 33,613 cases and 2,431,327 controls, confirming blood group A (OR = 1.19,95% CI: 1.13-1.25) and AB (OR = 1.09,95% CI: 1.03-1.16) associations with increased gastric cancer risk 2.

Interaction with H. pylori Infection

The blood type association is significantly modified by H. pylori cagA status, creating distinct risk profiles:

  • Blood type A individuals infected with cagA-positive H. pylori strains have a 1.42-fold increased risk (95% CI: 1.09-1.86) of intestinal metaplasia or dysplasia compared to blood type O individuals with the same infection 4
  • The combined risk of blood type A plus cagA-positive H. pylori infection yields an OR of 3.82 (95% CI: 2.80-5.20) compared to non-A blood groups with cagA-negative strains 4
  • Blood type A individuals are more susceptible to H. pylori infection itself (OR = 1.42; 95% CI: 1.05-1.93) 3
  • Paradoxically, among those with cagA-negative H. pylori or no infection, blood type A shows a protective effect (OR = 0.60; 95% CI: 0.38-0.94) 4

Clinical Integration with Other Risk Factors

Blood type should be considered within the comprehensive risk assessment framework outlined in current gastric cancer screening guidelines 5:

Primary Risk Factors to Assess Alongside Blood Type:

  • H. pylori infection status and cagA positivity - the most modifiable and important risk factor 6
  • Family history - first-degree relative with gastric cancer increases risk 2-3 fold, and when combined with blood type A, yields an OR of 2.61 (95% CI: 1.59-4.30) for dysplasia 7, 6
  • Geographic origin - first-generation immigrants from high-incidence regions (East Asia, Andean Latin America, Eastern Europe) 5, 6
  • Age - peak incidence in seventh decade 6
  • Male gender - approximately 2-fold increased risk 6
  • Tobacco exposure 5, 6
  • Persistent poverty - 43% higher mortality rates 6
  • Hereditary cancer syndromes (Lynch syndrome, familial adenomatous polyposis, etc.) 5

Practical Clinical Application

Blood type A should lower the threshold for gastric cancer screening when combined with other risk factors, though it is not sufficient alone to warrant screening 5, 8:

When to Consider Screening:

  • Blood type A PLUS first-degree relative with gastric cancer - particularly strong indication given combined OR of 2.61 for precancerous lesions 7
  • Blood type A PLUS cagA-positive H. pylori infection - highest risk group requiring H. pylori eradication and consideration for surveillance 4
  • Blood type A PLUS immigration from high-incidence region - especially first-generation immigrants 5, 6
  • Blood type A PLUS multiple modifiable risk factors (smoking, high salt diet, persistent poverty) 5, 6

Important Caveats:

Blood type is a non-modifiable risk factor - clinical efforts should prioritize modifiable factors including H. pylori eradication, smoking cessation, and dietary modification 8, 6

The absolute risk increase is modest - blood type A increases relative risk by approximately 20%, but the baseline risk in the general U.S. population remains low outside of high-risk groups 1, 2

Current U.S. guidelines do not include blood type in formal risk stratification algorithms, focusing instead on ethnicity, family history, H. pylori status, and hereditary syndromes 5

Mechanism and Precancerous Lesions

Blood type A is associated with increased risk of precancerous gastric lesions, not just invasive cancer:

  • Dysplasia risk - OR = 1.39 (95% CI: 1.12-1.73) for blood type A 7
  • Intestinal metaplasia risk - OR = 1.28 (95% CI: 1.06-1.53) for blood type A 7

This suggests blood type influences early stages of the gastric carcinogenesis cascade, particularly in the context of H. pylori-induced inflammation and progression through atrophic gastritis to intestinal metaplasia and dysplasia 4, 7.

References

Research

ABO blood group system and gastric cancer: a case-control study and meta-analysis.

International journal of molecular sciences, 2012

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Risk Factors for Gastric Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Gastric Cancer Risk Factors and Screening

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.